nothing unexpected. their loss was typical, but large nonetheless. and i cannot understand why this company cannot control their expenses. they lose way too much for a company who isnt developing any real or major drug.
they still maintain in this recent 10-Q that they expect initial sales of nicosan to be "insignificant" under line (7) and that worries me short term.
if you take into consideration that the factory will be complete in a year, then sales will start off slowly as per their "insignificant" language in the recent 10-Q.. then they will attain 200million in revenues by year 5...
i consider that we have a long way to go (1-2 years), with possible dilution in between which will probably dissuade any serious buying for a while.
i too expect the stock to jump when the loan is approved, but i also expect it to be temporary and sell back off a few weeks later.
i doubt this moves anywhere until we approach factory completion. and even then, we still have to wait for nicosan sales to mature apparently.
the only thing that will move this stock LONG TERM (not talking about a bounce on the loan news etc), IMO, is time. Time must pass and dilution must end for this to move.